Faricimab

VOYAGER shows Vabysmo yields vision gains, marked CST reductions and reduced retinal fluid across nAMD, DME and RVO in routine practice, with no new safety signals.

VOYAGER real-world data show Vabysmo improves vision and reduces retinal thickness across wet AMD, DME and RVO, with rapid anatomical drying and no new safety signals.

Dual Ang‑2/VEGF‑A inhibitor delivered vision gains, lesion regression and dosing intervals up to 20 weeks for most patients in a two‑year Asian PCV trial.

ARVO 2026: real‑world data show Vabysmo reduces retinal fluid in nAMD/DME; Susvimo enables sustained delivery with lower treatment burden; early vamikibart IL‑6 results; 45+ abstracts.

ARVO presentations: real-world Vabysmo data show retinal drying in wet AMD/DME; Susvimo demonstrates sustained delivery and reduced treatment burden; vamikibart shows early efficacy; >45 abstracts

Pharmaceuticals and diagnostics drive profit and earnings growth. Key approvals and advancements in therapies. Dividend increase proposed. Board changes announced. Positive 2026 outlook.

Vamikibart shows promise in treating UME, with significant vision improvements in trials, offering a non-steroid alternative with fewer side effects.